About us

Omnio AB is a biopharmaceutical company specialized in development of new drug products based on the protein plasminogen’s immune regulatory effects.  

Omnio focuses on developing a novel biological drug for chronic wound healing where initial investigator led treatments of patients with chronic wounds have shown great potential.

Our ambition is to transform todays wound healing treatment and provide an effective alternative to patients where curable treatment is absent.